COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients

{ 'indexed': {'date-parts': [[2023, 12, 2]], 'date-time': '2023-12-02T00:56:52Z', 'timestamp': 1701478612692}, 'reference-count': 55, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2023, 12, 1]], 'date-time': '2023-12-01T00:00:00Z', 'timestamp': 1701388800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2023, 12, 1]], 'date-time': '2023-12-01T00:00:00Z', 'timestamp': 1701388800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [{'DOI': '10.13039/100000871', 'name': 'Mayo Clinic', 'doi-asserted-by': 'crossref'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>The role of severe acute respiratory syndrome ' 'coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 ' '(COVID-19) in immunosuppressed individuals remains controversial. We describe the course of ' 'COVID-19 in patients who had received anti-CD20 therapy within the 3\xa0years prior to ' 'infection. We compared outcomes between those treated with and those not treated with high ' 'titer SARS-CoV2 convalescent plasma. We identified 144 adults treated at Mayo clinic sites ' 'who had received anti-CD20 therapies within a median of 5.9\xa0months prior to the COVID-19 ' 'index date. About one-third (34.7%) were hospitalized within 14\xa0days and nearly half ' '(47.9%) within 90\xa0days. COVID-19 directed therapy included anti-spike monoclonal ' 'antibodies (n\u2009=\u200930, 20.8%), and, among those hospitalized within 14\xa0days (n\u2009' '=\u200950), remdesivir (n\u2009=\u200945, 90.0%), glucocorticoids (n\u2009=\u200936, 72.0%) ' 'and convalescent plasma (n\u2009=\u200924, 48.0%). The duration from receipt of last dose of ' 'anti-CD20 therapy did not correlate with outcomes. The overall 90-day mortality rate was ' '14.7%. Administration of convalescent plasma within 14\xa0days of the COVID-19 diagnosis was ' 'not significantly associated with any study outcome. Further study of COVID-19 in ' 'CD20-depleted individuals is needed focusing on the early administration of new and ' 'potentially combination antiviral agents, associated or not with vaccine-boosted convalescent ' 'plasma.</jats:p>', 'DOI': '10.1038/s41598-023-48145-x', 'type': 'journal-article', 'created': {'date-parts': [[2023, 12, 1]], 'date-time': '2023-12-01T18:02:17Z', 'timestamp': 1701453737000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in ' 'immunosuppressed patients', 'prefix': '10.1038', 'volume': '13', 'author': [ {'given': 'Mary J.', 'family': 'Kasten', 'sequence': 'first', 'affiliation': []}, {'given': 'Brian D.', 'family': 'Lahr', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anusha', 'family': 'Parisapogu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zachary A.', 'family': 'Yetmar', 'sequence': 'additional', 'affiliation': []}, {'given': 'John C.', 'family': 'O’Horo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Robert', 'family': 'Orenstein', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pablo', 'family': 'Moreno Franco', 'sequence': 'additional', 'affiliation': []}, {'given': 'Raymund R.', 'family': 'Razonable', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paschalis', 'family': 'Vergidis', 'sequence': 'additional', 'affiliation': []}, {'given': 'Aditya S.', 'family': 'Shah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mark J.', 'family': 'Enzler', 'sequence': 'additional', 'affiliation': []}, {'given': 'David J.', 'family': 'Inwards', 'sequence': 'additional', 'affiliation': []}, {'given': 'Philippe R.', 'family': 'Bauer', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2023, 12, 1]]}, 'reference': [ { 'key': '48145_CR1', 'doi-asserted-by': 'publisher', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'volume': '386', 'author': 'J Hammond', 'year': '2022', 'unstructured': 'Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized ' 'adults with covid-19. N. Engl. J. Med. 386, 1397–1408. ' 'https://doi.org/10.1056/NEJMoa2118542 (2022).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '48145_CR2', 'doi-asserted-by': 'publisher', 'first-page': '305', 'DOI': '10.1056/NEJMoa2116846', 'volume': '386', 'author': 'RL Gottlieb', 'year': '2022', 'unstructured': 'Gottlieb, R. L. et al. Early remdesivir to prevent progression to severe ' 'covid-19 in outpatients. N. Engl. J. Med. 386, 305–315. ' 'https://doi.org/10.1056/NEJMoa2116846 (2022).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '48145_CR3', 'doi-asserted-by': 'publisher', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'volume': '384', 'author': 'RECOVERY Collaborative Group', 'year': '2021', 'unstructured': 'RECOVERY Collaborative Group et al. Dexamethasone in hospitalized ' 'patients with covid-19. N. Engl. J. Med. 384, 693–704. ' 'https://doi.org/10.1056/NEJMoa2021436 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '48145_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1317', 'DOI': '10.1001/jama.2020.17022', 'volume': '324', 'author': 'The Writing Committee for the REMAP-CAP Investigators', 'year': '2020', 'unstructured': 'The Writing Committee for the REMAP-CAP Investigators. Effect of ' 'hydrocortisone on mortality and organ support in patients with severe ' 'COVID-19: The remap-cap COVID-19 corticosteroid domain randomized ' 'clinical trial. JAMA 324, 1317–1329. ' 'https://doi.org/10.1001/jama.2020.17022 (2020).', 'journal-title': 'JAMA'}, { 'key': '48145_CR5', 'doi-asserted-by': 'publisher', 'first-page': '1019', 'DOI': '10.1016/j.chest.2020.10.054', 'volume': '159', 'author': 'EJ Cano', 'year': '2021', 'unstructured': 'Cano, E. J. et al. Impact of corticosteroids in coronavirus disease 2019 ' 'outcomes: Systematic review and meta-analysis. Chest 159, 1019–1040. ' 'https://doi.org/10.1016/j.chest.2020.10.054 (2021).', 'journal-title': 'Chest'}, { 'key': '48145_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1491', 'DOI': '10.1056/NEJMoa2100433', 'volume': '384', 'author': 'REMAP-CAP Investigators', 'year': '2021', 'unstructured': 'REMAP-CAP Investigators et al. Interleukin-6 receptor antagonists in ' 'critically ill patients with covid-19. N. Engl. J. Med. 384, 1491–1502. ' 'https://doi.org/10.1056/NEJMoa2100433 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '48145_CR7', 'doi-asserted-by': 'publisher', 'first-page': '795', 'DOI': '10.1056/NEJMoa2031994', 'volume': '384', 'author': 'AC Kalil', 'year': '2021', 'unstructured': 'Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults ' 'with covid-19. N. Engl. J. Med. 384, 795–807. ' 'https://doi.org/10.1056/NEJMoa2031994 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '48145_CR8', 'doi-asserted-by': 'publisher', 'first-page': '229', 'DOI': '10.1056/NEJMoa2029849', 'volume': '384', 'author': 'P Chen', 'year': '2021', 'unstructured': 'Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in ' 'outpatients with covid-19. N. Engl. J. Med. 384, 229–237. ' 'https://doi.org/10.1056/NEJMoa2029849 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '48145_CR9', 'doi-asserted-by': 'publisher', 'first-page': '238', 'DOI': '10.1056/NEJMoa2035002', 'volume': '384', 'author': 'DM Weinreich', 'year': '2021', 'unstructured': 'Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in ' 'outpatients with covid-19. N. Engl. J. Med. 384, 238–251. ' 'https://doi.org/10.1056/NEJMoa2035002 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '48145_CR10', 'unstructured': 'COVID-19 Treatment Guidelines Panel. Statement on Tixagevimab Plus ' 'Cilgavimab (Evusheld) as Pre-Exposure Prophylaxis of COVID-19. ' 'Coronavirus Disease (COVID-19) Treatment Guidelines (2023, accessed 4 ' 'Apr 2023). ' 'https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-evusheld/.'}, { 'key': '48145_CR11', 'doi-asserted-by': 'publisher', 'first-page': '1185', 'DOI': '10.1001/jama.2021.2747', 'volume': '325', 'author': 'P Janiaud', 'year': '2021', 'unstructured': 'Janiaud, P. et al. Association of convalescent plasma treatment with ' 'clinical outcomes in patients with COVID-19: A systematic review and ' 'meta-analysis. JAMA 325, 1185–1195. ' 'https://doi.org/10.1001/jama.2021.2747 (2021).', 'journal-title': 'JAMA'}, { 'key': '48145_CR12', 'doi-asserted-by': 'publisher', 'first-page': '1015', 'DOI': '10.1056/NEJMoa2031893', 'volume': '384', 'author': 'MJ Joyner', 'year': '2021', 'unstructured': 'Joyner, M. J. et al. Convalescent plasma antibody levels and the risk of ' 'death from covid-19. N. Engl. J. Med. 384, 1015–1027. ' 'https://doi.org/10.1056/NEJMoa2031893 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '48145_CR13', 'unstructured': 'FDA News Release. FDA issues emergency use authorization for ' 'convalescent plasma as potential promising COVID–19 treatment, another ' 'achievement in administration’s fight against pandemic (2023, accessed 4 ' 'Apr 2023). ' 'https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment.'}, { 'key': '48145_CR14', 'unstructured': 'FDA In Brief: FDA updates emergency use authorization for COVID-19 ' 'convalescent plasma to reflect new data (2023, accessed 4 Apr 2023). ' 'https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-data.'}, { 'key': '48145_CR15', 'unstructured': 'COVID-19 Treatment Guidelines Panel. COVID-19 Treatment Guidelines: ' 'COVID-19 Convalescent Plasma (2023, accessed 15 Sep 2023). ' 'https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/covid-19-convalescent-plasma/.'}, { 'key': '48145_CR16', 'unstructured': 'Centers for Disease Control and Prevention. COVID Data Tracker, COVID-19 ' 'Vaccinations in the United States (2023, accessed 3 Mar 2023). ' 'https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5.'}, { 'key': '48145_CR17', 'doi-asserted-by': 'publisher', 'first-page': 'e312', 'DOI': '10.1016/S2352-3026(21)00073-9', 'volume': '8', 'author': 'C Sun', 'year': '2021', 'unstructured': 'Sun, C., Pleyer, C. & Wiestner, A. COVID-19 vaccines for patients with ' 'haematological conditions. Lancet Haematol. 8, e312–e314. ' 'https://doi.org/10.1016/S2352-3026(21)00073-9 (2021).', 'journal-title': 'Lancet Haematol.'}, { 'key': '48145_CR18', 'doi-asserted-by': 'publisher', 'first-page': '3165', 'DOI': '10.1182/blood.2021011568', 'volume': '137', 'author': 'Y Herishanu', 'year': '2021', 'unstructured': 'Herishanu, Y. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in ' 'patients with chronic lymphocytic leukemia. Blood 137, 3165–3173. ' 'https://doi.org/10.1182/blood.2021011568 (2021).', 'journal-title': 'Blood'}, { 'key': '48145_CR19', 'doi-asserted-by': 'publisher', 'first-page': '672', 'DOI': '10.1001/jamainternmed.2021.0366', 'volume': '181', 'author': 'RA Harvey', 'year': '2021', 'unstructured': 'Harvey, R. A. et al. Association of SARS-CoV-2 seropositive antibody ' 'test with risk of future infection. JAMA Intern. Med. 181, 672–679. ' 'https://doi.org/10.1001/jamainternmed.2021.0366 (2021).', 'journal-title': 'JAMA Intern. Med.'}, { 'key': '48145_CR20', 'doi-asserted-by': 'publisher', 'first-page': '436', 'DOI': '10.3390/v13030436', 'volume': '13', 'author': 'MM Biernat', 'year': '2021', 'unstructured': 'Biernat, M. M. et al. Early administration of convalescent plasma ' 'improves survival in patients with hematological malignancies and ' 'COVID-19. Viruses 13, 436. https://doi.org/10.3390/v13030436 (2021).', 'journal-title': 'Viruses'}, { 'key': '48145_CR21', 'doi-asserted-by': 'publisher', 'first-page': 'e419', 'DOI': '10.1016/S2665-9913(21)00059-X', 'volume': '3', 'author': 'J Avouac', 'year': '2021', 'unstructured': 'Avouac, J. et al. COVID-19 outcomes in patients with inflammatory ' 'rheumatic and musculoskeletal diseases treated with rituximab: A cohort ' 'study. Lancet Rheumatol. 3, e419–e426. ' 'https://doi.org/10.1016/S2665-9913(21)00059-X (2021).', 'journal-title': 'Lancet Rheumatol.'}, { 'key': '48145_CR22', 'doi-asserted-by': 'publisher', 'first-page': 'e815', 'DOI': '10.1093/cid/ciab072', 'volume': '73', 'author': 'MK Hensley', 'year': '2021', 'unstructured': 'Hensley, M. K. et al. Intractable coronavirus disease 2019 (COVID-19) ' 'and prolonged severe acute respiratory syndrome coronavirus 2 ' '(SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell ' 'therapy recipient: A case study. Clin. Infect. Dis. 73, e815–e821. ' 'https://doi.org/10.1093/cid/ciab072 (2021).', 'journal-title': 'Clin. Infect. Dis.'}, { 'key': '48145_CR23', 'doi-asserted-by': 'publisher', 'first-page': '131', 'DOI': '10.1186/s13045-020-00968-1', 'volume': '13', 'author': 'G Lancman', 'year': '2020', 'unstructured': 'Lancman, G., Mascarenhas, J. & Bar-Natan, M. Severe COVID-19 virus ' 'reactivation following treatment for B cell acute lymphoblastic ' 'leukemia. J. Hematol. Oncol. 13, 131. ' 'https://doi.org/10.1186/s13045-020-00968-1 (2020).', 'journal-title': 'J. Hematol. Oncol.'}, { 'key': '48145_CR24', 'doi-asserted-by': 'publisher', 'first-page': '820', 'DOI': '10.1017/ice.2021.120', 'volume': '43', 'author': 'CM Hughes', 'year': '2022', 'unstructured': 'Hughes, C. M. et al. Clinical illness with viable severe acute ' 'respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days ' 'after infection in an immunocompromised patient. Infect. Control Hosp. ' 'Epidemiol. 43, 820–822. https://doi.org/10.1017/ice.2021.120 (2022).', 'journal-title': 'Infect. Control Hosp. Epidemiol.'}, { 'key': '48145_CR25', 'doi-asserted-by': 'publisher', 'first-page': 'e20200678', 'DOI': '10.1084/jem.20200678', 'volume': '217', 'author': 'SA Vardhana', 'year': '2020', 'unstructured': 'Vardhana, S. A. & Wolchok, J. D. The many faces of the anti-COVID immune ' 'response. J. Exp. Med. 217, e20200678. ' 'https://doi.org/10.1084/jem.20200678 (2020).', 'journal-title': 'J. Exp. Med.'}, { 'key': '48145_CR26', 'doi-asserted-by': 'publisher', 'first-page': '1713', 'DOI': '10.1002/art.41728', 'volume': '73', 'author': 'MA Rutherford', 'year': '2021', 'unstructured': 'Rutherford, M. A. et al. Risk factors for severe outcomes in patients ' 'with systemic vasculitis and COVID-19: A binational, registry-based ' 'cohort study. Arthrit. Rheumatol. 73, 1713–1719. ' 'https://doi.org/10.1002/art.41728 (2021).', 'journal-title': 'Arthrit. Rheumatol.'}, { 'key': '48145_CR27', 'doi-asserted-by': 'publisher', 'first-page': '11926', 'DOI': '10.26355/eurrev_202011_23852', 'volume': '24', 'author': 'JS Kim', 'year': '2020', 'unstructured': 'Kim, J. S. et al. Clinical characteristics and mortality of patients ' 'with hematologic malignancies and COVID-19: A systematic review. Eur. ' 'Rev. Med. Pharmacol. Sci. 24, 11926–11933. ' 'https://doi.org/10.26355/eurrev_202011_23852 (2020).', 'journal-title': 'Eur. Rev. Med. Pharmacol. Sci.'}, { 'key': '48145_CR28', 'doi-asserted-by': 'publisher', 'first-page': '2881', 'DOI': '10.1182/blood.2020008824', 'volume': '136', 'author': 'A Vijenthira', 'year': '2020', 'unstructured': 'Vijenthira, A. et al. Outcomes of patients with hematologic malignancies ' 'and COVID-19: A systematic review and meta-analysis of 3377 patients. ' 'Blood 136, 2881–2892. https://doi.org/10.1182/blood.2020008824 (2020).', 'journal-title': 'Blood'}, { 'key': '48145_CR29', 'doi-asserted-by': 'publisher', 'first-page': 'e185', 'DOI': '10.1016/S2352-3026(20)30429-4', 'volume': '8', 'author': 'A Sharma', 'year': '2021', 'unstructured': 'Sharma, A. et al. Clinical characteristics and outcomes of COVID-19 in ' 'haematopoietic stem-cell transplantation recipients: An observational ' 'cohort study. Lancet Haematol. 8, e185–e193. ' 'https://doi.org/10.1016/S2352-3026(20)30429-4 (2021).', 'journal-title': 'Lancet Haematol.'}, { 'key': '48145_CR30', 'doi-asserted-by': 'publisher', 'first-page': '108723', 'DOI': '10.1016/j.clim.2021.108723', 'volume': '227', 'author': 'A Kenig', 'year': '2021', 'unstructured': 'Kenig, A., Ishay, Y., Kharouf, F. & Rubin, L. Treatment of B-cell ' 'depleted COVID-19 patients with convalescent plasma and plasma-based ' 'products. Clin. Immunol. 227, 108723. ' 'https://doi.org/10.1016/j.clim.2021.108723 (2021).', 'journal-title': 'Clin. Immunol.'}, { 'key': '48145_CR31', 'doi-asserted-by': 'publisher', 'first-page': '2290', 'DOI': '10.1182/blood.2020008423', 'volume': '136', 'author': 'T Hueso', 'year': '2020', 'unstructured': 'Hueso, T. et al. Convalescent plasma therapy for B-cell-depleted ' 'patients with protracted COVID-19. Blood 136, 2290–2295. ' 'https://doi.org/10.1182/blood.2020008423 (2020).', 'journal-title': 'Blood'}, { 'key': '48145_CR32', 'doi-asserted-by': 'publisher', 'first-page': '1490', 'DOI': '10.1080/10428194.2021.1872070', 'volume': '62', 'author': 'S Ferrari', 'year': '2021', 'unstructured': 'Ferrari, S., Caprioli, C., Weber, A., Rambaldi, A. & Lussana, F. ' 'Convalescent hyperimmune plasma for chemo-immunotherapy induced ' 'immunodeficiency in COVID-19 patients with hematological malignancies. ' 'Leuk. Lymphom. 62, 1490–1496. ' 'https://doi.org/10.1080/10428194.2021.1872070 (2021).', 'journal-title': 'Leuk. Lymphom.'}, { 'key': '48145_CR33', 'doi-asserted-by': 'publisher', 'first-page': '1167', 'DOI': '10.1001/jamaoncol.2021.1799', 'volume': '7', 'author': 'MA Thompson', 'year': '2021', 'unstructured': 'Thompson, M. A. et al. Association of convalescent plasma therapy with ' 'survival in patients with hematologic cancers and COVID-19. JAMA Oncol. ' '7, 1167–1175. https://doi.org/10.1001/jamaoncol.2021.1799 (2021).', 'journal-title': 'JAMA Oncol.'}, { 'key': '48145_CR34', 'doi-asserted-by': 'publisher', 'first-page': '4141', 'DOI': '10.1002/jmv.26921', 'volume': '93', 'author': 'V Gerber', 'year': '2021', 'unstructured': 'Gerber, V. et al. Protracted SARS-CoV-2 pneumonia with rituximab ' 'treatment: About two cases. J. Med. Virol. 93, 4141–4144. ' 'https://doi.org/10.1002/jmv.26921 (2021).', 'journal-title': 'J. Med. Virol.'}, { 'key': '48145_CR35', 'doi-asserted-by': 'publisher', 'first-page': '114', 'DOI': '10.1016/j.ijid.2021.06.034', 'volume': '109', 'author': 'FW Hamilton', 'year': '2021', 'unstructured': 'Hamilton, F. W., Lee, T., Arnold, D. T., Lilford, R. & Hemming, K. Is ' 'convalescent plasma futile in COVID-19? A Bayesian re-analysis of the ' 'RECOVERY randomized controlled trial. Int. J. Infect. Dis. 109, 114–117. ' 'https://doi.org/10.1016/j.ijid.2021.06.034 (2021).', 'journal-title': 'Int. J. Infect. Dis.'}, { 'key': '48145_CR36', 'doi-asserted-by': 'publisher', 'first-page': '2503', 'DOI': '10.1111/trf.16525', 'volume': '61', 'author': 'JW Senefeld', 'year': '2021', 'unstructured': 'Senefeld, J. W. et al. Use of convalescent plasma in COVID-19 patients ' 'with immunosuppression. Transfusion 61, 2503–2511. ' 'https://doi.org/10.1111/trf.16525 (2021).', 'journal-title': 'Transfusion'}, { 'key': '48145_CR37', 'doi-asserted-by': 'publisher', 'first-page': 'e2250647', 'DOI': '10.1001/jamanetworkopen.2022.50647', 'volume': '6', 'author': 'JW Senefeld', 'year': '2023', 'unstructured': 'Senefeld, J. W. et al. COVID-19 convalescent plasma for the treatment of ' 'immunocompromised patients: A systematic review and meta-analysis. JAMA ' 'Netw. Open 6, e2250647. ' 'https://doi.org/10.1001/jamanetworkopen.2022.50647 (2023).', 'journal-title': 'JAMA Netw. Open'}, { 'key': '48145_CR38', 'doi-asserted-by': 'crossref', 'unstructured': 'von Elm, E. et al. The strengthening the reporting of observational ' 'studies in epidemiology (STROBE) statement: Guidelines for reporting ' 'observational studies. Equator Network (2023, accessed 18 Jan 2023). ' 'https://www.equator-network.org/reporting-guidelines/strobe/.', 'DOI': '10.1097/EDE.0b013e3181577654'}, { 'key': '48145_CR39', 'doi-asserted-by': 'publisher', 'first-page': '503', 'DOI': '10.1097/CCM.0000000000004817', 'volume': '49', 'author': 'A Tong', 'year': '2021', 'unstructured': 'Tong, A. et al. Core outcome measures for trials in people with ' 'coronavirus disease 2019: Respiratory failure, multiorgan failure, ' 'shortness of breath, and recovery. Crit. Care Med. 49, 503–516. ' 'https://doi.org/10.1097/CCM.0000000000004817 (2021).', 'journal-title': 'Crit. Care Med.'}, { 'key': '48145_CR40', 'doi-asserted-by': 'publisher', 'first-page': '601', 'DOI': '10.1016/j.mayocp.2020.12.006', 'volume': '96', 'author': "JC O'Horo", 'year': '2021', 'unstructured': 'O’Horo, J. C. et al. Outcomes of COVID-19 with the Mayo Clinic model of ' 'care and research. Mayo Clin. Proc. 96, 601–618. ' 'https://doi.org/10.1016/j.mayocp.2020.12.006 (2021).', 'journal-title': 'Mayo Clin. Proc.'}, { 'key': '48145_CR41', 'unstructured': 'O’Shaughnessy, J. Revised Letter of Authorization (2021, accessed 9 Nov ' '2023). https://www.fda.gov/media/141477/download.'}, { 'key': '48145_CR42', 'doi-asserted-by': 'publisher', 'first-page': 'e241', 'DOI': '10.1136/annrheumdis-2020-218957', 'volume': '81', 'author': 'F Jeny', 'year': '2022', 'unstructured': 'Jeny, F. et al. Correspondence on “glucocorticoid-induced relapse of ' 'COVID-19 in a patient with sarcoidosis”. Ann. Rheum. Dis. 81, e241. ' 'https://doi.org/10.1136/annrheumdis-2020-218957 (2022).', 'journal-title': 'Ann. Rheum. Dis.'}, { 'key': '48145_CR43', 'doi-asserted-by': 'publisher', 'first-page': 'e1003501', 'DOI': '10.1371/journal.pmed.1003501', 'volume': '17', 'author': 'MS Kim', 'year': '2020', 'unstructured': 'Kim, M. S., An, M. H., Kim, W. J. & Hwang, T. H. Comparative efficacy ' 'and safety of pharmacological interventions for the treatment of ' 'COVID-19: A systematic review and network meta-analysis. PLoS Med. 17, ' 'e1003501. https://doi.org/10.1371/journal.pmed.1003501 (2020).', 'journal-title': 'PLoS Med.'}, { 'key': '48145_CR44', 'doi-asserted-by': 'publisher', 'first-page': '1980', 'DOI': '10.1007/s11606-022-07511-7', 'volume': '37', 'author': 'M Rubio-Rivas', 'year': '2022', 'unstructured': 'Rubio-Rivas, M. et al. WHO ordinal scale and inflammation risk ' 'categories in COVID-19. Comparative study of the severity scales. J. ' 'Gen. Intern. Med. 37, 1980–1987. ' 'https://doi.org/10.1007/s11606-022-07511-7 (2022).', 'journal-title': 'J. Gen. Intern. Med.'}, { 'key': '48145_CR45', 'unstructured': 'R Core Team. R: A language and environment for statistical computing. R ' 'Foundation for statistical computing, Vienna, Austria (2020, accessed 18 ' 'Jan 2023). https://www.R-project.org/.'}, { 'key': '48145_CR46', 'doi-asserted-by': 'publisher', 'first-page': 'e2248664', 'DOI': '10.1001/jamanetworkopen.2022.48664', 'volume': '5', 'author': 'JB Smith', 'year': '2022', 'unstructured': 'Smith, J. B., Gonzales, E. G., Li, B. H. & Langer-Gould, A. Analysis of ' 'rituximab use, time between rituximab and SARS-CoV-2 vaccination, and ' 'COVID-19 hospitalization or death in patients with multiple sclerosis. ' 'JAMA Netw. Open 5, e2248664. ' 'https://doi.org/10.1001/jamanetworkopen.2022.48664 (2022).', 'journal-title': 'JAMA Netw. Open'}, { 'key': '48145_CR47', 'doi-asserted-by': 'publisher', 'first-page': '2805', 'DOI': '10.1007/s00277-021-04662-1', 'volume': '100', 'author': 'H Levavi', 'year': '2021', 'unstructured': 'Levavi, H., Lancman, G. & Gabrilove, J. Impact of rituximab on COVID-19 ' 'outcomes. Ann. Hematol. 100, 2805–2812 (2021).', 'journal-title': 'Ann. Hematol.'}, { 'key': '48145_CR48', 'doi-asserted-by': 'publisher', 'first-page': '892', 'DOI': '10.1111/bjh.17937', 'volume': '196', 'author': 'S Booth', 'year': '2021', 'unstructured': 'Booth, S. et al. Key findings from the UKCCMP cohort of 877 patients ' 'with haematological malignancy and COVID-19: Disease control as an ' 'important factor relative to recent chemotherapy or anti-CD20 therapy. ' 'Br. J. Haematol. 196, 892–901 (2021).', 'journal-title': 'Br. J. Haematol.'}, { 'key': '48145_CR49', 'doi-asserted-by': 'publisher', 'first-page': 'e2136697', 'DOI': '10.1001/jamanetworkopen', 'volume': '4', 'author': 'KA McKay', 'year': '2021', 'unstructured': 'McKay, K. A. et al. Rituximab infusion timing, cumulative dose, and ' 'hospitalization for COVID-19 in persons with multiple sclerosis in ' 'Sweden. JAMA. Netw. Open. 4, e2136697. ' 'https://doi.org/10.1001/jamanetworkopen (2021).', 'journal-title': 'JAMA. Netw. Open.'}, { 'key': '48145_CR50', 'doi-asserted-by': 'publisher', 'first-page': '1590', 'DOI': '10.1056/NEJMoa2209502', 'volume': '389', 'author': 'B Misset', 'year': '2023', 'unstructured': 'Misset, B. et al. Convalescent plasma for Covid-19-induced ARDS in ' 'mechanically ventilated patients. NEJM 389, 1590–1600 (2023).', 'journal-title': 'NEJM'}, { 'key': '48145_CR51', 'doi-asserted-by': 'publisher', 'first-page': '2077', 'DOI': '10.1093/cid/ciad088', 'volume': '76', 'author': 'AC Levine', 'year': '2023', 'unstructured': 'Levine, A. C. et al. COVID-19 convalescent plasma outpatient therapy to ' 'prevent outpatient hospitalization: A meta-analysis of individual ' 'participant data from five randomized trials. Clin. Infect. Dis. 76, ' '2077–2086 (2023).', 'journal-title': 'Clin. Infect. Dis.'}, { 'key': '48145_CR52', 'doi-asserted-by': 'publisher', 'first-page': '5951', 'DOI': '10.1182/bloodadvances.2022008932', 'volume': '6', 'author': 'JG Ripoll', 'year': '2022', 'unstructured': 'Ripoll, J. G. et al. Vaccine-boosted convalescent plasma therapy for ' 'patients with immunosuppression and COVID-19. Blood Adv. 6, 5951–5955 ' '(2022).', 'journal-title': 'Blood Adv.'}, { 'key': '48145_CR53', 'doi-asserted-by': 'publisher', 'first-page': '6922', 'DOI': '10.1038/s41467-022-34657-z', 'volume': '13', 'author': 'LB Cook', 'year': '2022', 'unstructured': 'Cook, L. B. et al. Third primary SARS-CoV-2 mRNA vaccines enhance ' 'antibody responses in most patients with haematological malignancies. ' 'Nat Commun. 13, 6922. https://doi.org/10.1038/s41467-022-34657-z (2022).', 'journal-title': 'Nat Commun.'}, { 'key': '48145_CR54', 'doi-asserted-by': 'publisher', 'first-page': '923', 'DOI': '10.1093/cid/ciac847', 'volume': '76', 'author': 'CA Trottier', 'year': '2023', 'unstructured': 'Trottier, C. A. et al. Dual antiviral therapy for persistent coronavirus ' 'disease 2019 and associated organizing pneumonia in an immunocompromised ' 'host. Clin. Infect. Dis. 76, 923–925 (2023).', 'journal-title': 'Clin. Infect. Dis.'}, { 'key': '48145_CR55', 'doi-asserted-by': 'publisher', 'first-page': '926', 'DOI': '10.1093/cid/ciac868', 'volume': '76', 'author': 'ES Ford', 'year': '2023', 'unstructured': 'Ford, E. S. et al. Successful treatment of prolonged, severe coronavirus ' 'disease 2019 lower respiratory tract disease in a B cell acute ' 'lymphoblastic leukemia patient with an extended course of remdesivir and ' 'nirmatrelvir/ritonavir. Clin. Infect. Dis. 76, 926–929 (2023).', 'journal-title': 'Clin. Infect. Dis.'}], 'container-title': 'Scientific Reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41598-023-48145-x.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-023-48145-x', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-023-48145-x.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 12, 1]], 'date-time': '2023-12-01T18:11:18Z', 'timestamp': 1701454278000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-023-48145-x'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 12, 1]]}, 'references-count': 55, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2023, 12]]}}, 'alternative-id': ['48145'], 'URL': 'http://dx.doi.org/10.1038/s41598-023-48145-x', 'relation': {}, 'ISSN': ['2045-2322'], 'subject': ['Multidisciplinary'], 'container-title-short': 'Sci Rep', 'published': {'date-parts': [[2023, 12, 1]]}, 'assertion': [ { 'value': '22 September 2023', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '22 November 2023', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '1 December 2023', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'Mary J. Kasten, M.D.: Stockholder: Abbott Laboratories, AbbVie, Amgen, Eli ' 'Lilly, Bristol Myers Squib, Amgen, Merck, GlaxoSmithKline, Baxter ' 'International, Pfizer, CVS Health Corporation, Viatris Inc, Medtronic, Zimmer ' 'Biomet, Masimo Corp, Takeda Pharmaceutical\n' 'John C. O’Horo, M.D., M.P.H.: Grants from Nference, Inc and the MITRE ' 'corporation for COVID-19 research unrelated to the present work.\n' 'Raymund R. Razonable, M.D.: research grants (funds to the institution) from ' 'Gilead, Regeneron and Roche; member of the Data and Safety Monitoring Board ' '(Novartis) and Endpoint Adjudication Committee (Allovir); member of the Board ' 'of Directors, American Society of Transplantation\n' 'Paschalis Vergidis, M.D.: research support from Ansun, Cidara, Scynexis and ' 'consultant AbbVie with all fees being paid to Mayo Clinic\n' 'All other authors declare no conflicts of interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '21249'}